Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Liabilities and Shareholders Equity: 2022-2025

Historic Liabilities and Shareholders Equity for Corvus Pharmaceuticals (CRVS) over the last 4 years, with Sep 2025 value amounting to $80.5 million.

  • Corvus Pharmaceuticals' Liabilities and Shareholders Equity rose 36.83% to $80.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $298.3 million, marking a year-over-year increase of 42.71%. This contributed to the annual value of $68.9 million for FY2024, which is 51.27% up from last year.
  • Corvus Pharmaceuticals' Liabilities and Shareholders Equity amounted to $80.5 million in Q3 2025, which was down 10.05% from $89.5 million recorded in Q2 2025.
  • Corvus Pharmaceuticals' Liabilities and Shareholders Equity's 5-year high stood at $101.3 million during Q1 2022, with a 5-year trough of $40.1 million in Q1 2024.
  • Moreover, its 3-year median value for Liabilities and Shareholders Equity was $58.8 million (2024), whereas its average is $61.4 million.
  • In the last 5 years, Corvus Pharmaceuticals' Liabilities and Shareholders Equity slumped by 42.54% in 2023 and then spiked by 51.27% in 2024.
  • Over the past 4 years, Corvus Pharmaceuticals' Liabilities and Shareholders Equity (Quarterly) stood at $68.2 million in 2022, then plummeted by 33.25% to $45.6 million in 2023, then soared by 51.27% to $68.9 million in 2024, then skyrocketed by 36.83% to $80.5 million in 2025.
  • Its Liabilities and Shareholders Equity was $80.5 million in Q3 2025, compared to $89.5 million in Q2 2025 and $59.4 million in Q1 2025.